NCT01927107

Brief Summary

The global obesity epidemic presents an unprecedented challenge to the public health worldwide. The factors associated with obesity are complex, and include health behaviors, such as eating habits and daily physical activity, and broader social, environmental and biological determinants that influence these health behaviors. The intestinal microbiota has several beneficial functions related to host health and accumulating evidence indicates that the gut microbiota plays a significant role in the development of obesity, obesity-associated inflammation and insulin resistance. Experimental studies reveal a shift in the abundance of Bacteroidetes and Firmicutes. Presumably, obesity affects the diversity of the gut microbiota and, probably, the way individuals harvest energy from nutrients. Differences in community composition, functional genes and metabolic activities of the gut microbiota appear to distinguish lean vs obese individuals, suggesting that gut 'dysbiosis' contributes to the development of obesity and/or its complications. Recent studies have suggested some beneficial effects of probiotics and/or prebiotics on obesity and metabolic syndrome in adults; such experience is limited in children and adolescents. The aim of this study was to evaluate potential effects of add-on probiotics to standard therapy on anthropometric measurements, lipid profile and oxidative stress parameters in children.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable obesity

Timeline
Completed

Started Apr 2012

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2012

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

August 16, 2013

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 22, 2013

Completed
Last Updated

July 28, 2017

Status Verified

July 1, 2017

Enrollment Period

1.3 years

First QC Date

August 16, 2013

Last Update Submit

July 25, 2017

Conditions

Keywords

probioticsobesityoxidative stress

Outcome Measures

Primary Outcomes (1)

  • Obesity related anthropometric measurements

    Change of obesity related anthropometric measurements including weight, body mass index, upper arm circumference, tirceps skinfold thickness, waist and hip circumference

    30th days

Secondary Outcomes (2)

  • Evaluation of biochemical indices and oxidative stress

    30th days

  • Safety

    30th days

Study Arms (2)

Probiotic mixture

ACTIVE COMPARATOR

Probiotic mixture including Lactobacillus acidophilus (4.3x108CFU/per sachet), Lactobacillus rhamnosus (4.3x108CFU/ per sachet), Bifidobacterium bifidum (4.3x108CFU/ per sachet), Bifidobacterium longum (4.3x108CFU/ per sachet), Enterococcus faecium (8.2x108CFU/ per sachet, per oral daily for 30 days in addition to standard approach

Dietary Supplement: Probiotics mixture

Control

ACTIVE COMPARATOR

Standard diet therapy

Dietary Supplement: Probiotics mixture

Interventions

Probiotics mixtureDIETARY_SUPPLEMENT

Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy

ControlProbiotic mixture

Eligibility Criteria

Age5 Years - 17 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children with obesity according to anthropometric measurements with appropriate weight for age

You may not qualify if:

  • coexistence of secondary obesity, malignancy, immune deficiency, collagen vascular diseases, congenital anomalies, neurological findings, children with receiving concomitant any drugs related chronic condition or antibiotics. Children with exogenous obesity who have also insulin resistance and /or hypertension were also excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Ener C Dinleyici, MD

    Eskisehir Osmangazi University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor in Pediatrics

Study Record Dates

First Submitted

August 16, 2013

First Posted

August 22, 2013

Study Start

April 1, 2012

Primary Completion

August 1, 2013

Study Completion

August 1, 2013

Last Updated

July 28, 2017

Record last verified: 2017-07